Sickle Cell Disease Clinical Trials in Birmingham, Alabama

12 studies are recruiting for sickle cell disease in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Univ of Alabama Birmingham, Birmingham, Alabama

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Uni of Alabama at Birmingham, Birmingham, Alabama

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

   This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   9 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT07187973 on ClinicalTrials.gov

4. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   University Of Alabama, Birmingham, Alabama

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

5. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants …

   Stage

   Phase 1

   Ages

   12 to 55

   Site

   University of Alabama Birmingham, Birmingham, Alabama

   Locations

   10 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06546670 on ClinicalTrials.gov

6. SCD Stem Cell Mobilization and Apheresis Using Motixafortide

   This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06442761 on ClinicalTrials.gov

7. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study detai…

   Stage

   Phase 3

   Ages

   10 to 65

   Site

   University of Alabama at Birmingham- Site Number : 8400003, Birmingham, Alabama

   Locations

   53 in total

   Run by

   Sanofi

   See if you can join NCT06975865 on ClinicalTrials.gov

8. Early Life Exposures Among Children With Sickle Cell Disease

   This study is being conducted to determine the relationship between early childhood exposures, such as Adverse Childhood Experiences, Social Determinants of Health and nutrition/breastfeeding, among children with sickle cell disease, and behavioral interventions aimed to reshape psychological resil…

   Stage

   Not phased

   Ages

   18 to 50

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05377372 on ClinicalTrials.gov

9. Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

   This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

   Stage

   Phase 4

   Ages

   0 to 100

   Site

   University Of Alabama, Birmingham, Alabama

   Locations

   31 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04657822 on ClinicalTrials.gov

10. Cognitive Remediation Intervention to Prepare for Transition of Care

    Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.

    Stage

    Phase 2

    Ages

    10 to 18

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05336201 on ClinicalTrials.gov

11. A Long-term Follow-up Study in Patients Who Received BEAM-101

    This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed fo…

    Stage

    Not phased

    Ages

    14 to 37

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    17 in total

    Run by

    Beam Therapeutics Inc.

    See if you can join NCT07373639 on ClinicalTrials.gov

12. Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

    The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Alabama, Birmingham (UAB), Birmingham, Alabama

    Locations

    9 in total

    Run by

    RTI International

    See if you can join NCT06385886 on ClinicalTrials.gov